Insider Selling: Avanos Medical, Inc. (NYSE:AVNS) SVP Sells 7,000 Shares of Stock

Avanos Medical, Inc. (NYSE:AVNS) SVP Kerr Holbrook sold 7,000 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares in the company, valued at approximately $1,251,216.75. This represents a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Avanos Medical Trading Down 0.8 %

Shares of AVNS stock traded down $0.12 on Monday, reaching $15.12. 226,145 shares of the company’s stock were exchanged, compared to its average volume of 541,257. Avanos Medical, Inc. has a 52 week low of $14.40 and a 52 week high of $25.36. The stock has a market capitalization of $695.43 million, a PE ratio of 44.59 and a beta of 1.17. The company’s fifty day simple moving average is $16.01 and its 200 day simple moving average is $19.30. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. The business had revenue of $179.60 million for the quarter, compared to analyst estimates of $177.23 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. As a group, analysts forecast that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Institutional Trading of Avanos Medical

Several institutional investors and hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. boosted its stake in shares of Avanos Medical by 27.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock valued at $47,941,000 after buying an additional 644,267 shares in the last quarter. Tributary Capital Management LLC lifted its stake in shares of Avanos Medical by 38.1% during the fourth quarter. Tributary Capital Management LLC now owns 893,008 shares of the company’s stock worth $14,217,000 after purchasing an additional 246,379 shares in the last quarter. Brown Advisory Inc. increased its position in shares of Avanos Medical by 12.0% during the fourth quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company’s stock worth $30,329,000 after acquiring an additional 204,218 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in Avanos Medical by 43.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company’s stock worth $7,874,000 after buying an additional 148,902 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Avanos Medical by 189.8% during the fourth quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company’s stock valued at $3,210,000 after purchasing an additional 132,063 shares during the last quarter. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.